Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Quanterix's Business Segments
Quanterix's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
7
Largest Segment
Product
Total Revenue
$ 33
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product0%
- Consumable and other products0%
- Simoa Product Revenue94%
- Service and other revenue58.9%
- Spatial Product Revenue54.8%
- Simoa Service and Other Revenue38.6%
- Other services14.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 49 | - |
| Consumable and other products | $ 41 | - |
| Simoa Product Revenue | $ 31 | 94% |
Revenue by Product & Service Category - FY
- Product71.3%
- Simoa Product Revenue43%
- Consumable and other products34.8%
- Spatial Product Revenue28.4%
- Service and other revenue27.4%
- Simoa Service and Other Revenue18.3%
- Spatial Service and Other Revenue9.1%
- Research services7.9%
- Service-type warranties7.6%
- Other services3.1%
- License and Service1.3%
- Instruments0.5%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 23 | 71.3% |
| Simoa Product Revenue | $ 14 | 43% |
| Consumable and other products | $ 11 | 34.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
9 more categories available
Sign in to unlock the full Quanterix dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Product0%
- Consumable and other products0%
- Simoa Product Revenue94%
- Service and other revenue58.9%
- Spatial Product Revenue54.8%
- Simoa Service and Other Revenue38.6%
- Other services14.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 49 | - |
| Consumable and other products | $ 41 | - |
| Simoa Product Revenue | $ 31 | 94% |
4 more segments available
Sign in to unlock the full Quanterix dataset.
Description of Quanterix
Quanterix Corp is a biotech company that focuses on the development and commercialization of ultra-sensitive digital biomarker analysis solutions.
The company was founded in 2007 by David Walt, who is a pioneer in microarray technology.
Quanterix Corp aims to revolutionize the way diseases are detected and measured by providing accurate and precise biomarker measurements that can help diagnose and treat diseases at an earlier stage.
The company's flagship product is the Simoa system, which is a fully automated digital immunoassay platform that can detect and measure low-abundance biomolecules with unprecedented sensitivity.
Simoa uses single-molecule detection technology to accurately quantify proteins, DNA, and RNA molecules in biological samples, allowing scientists and clinicians to gain new insights into disease mechanisms and improve disease diagnosis and treatment.
Quanterix Corp's technology has a wide range of applications, including oncology, neurology, cardiology, infectious diseases, inflammation, and autoimmune diseases.
The company collaborates with leading academic institutions, pharmaceutical companies, and diagnostic companies to validate its technology and develop innovative diagnostic assays.
Quanterix Corp has received numerous awards for its technology, including being named a Technology Pioneer by the World Economic Forum, one of the 50 Smartest Companies by MIT Technology Review, and one of the Top 10 Innovations of the Year by The Scientist magazine.
The company is headquartered in Billerica, Massachusetts, and has offices and subsidiaries in Europe and Asia.
The company was founded in 2007 by David Walt, who is a pioneer in microarray technology.
Quanterix Corp aims to revolutionize the way diseases are detected and measured by providing accurate and precise biomarker measurements that can help diagnose and treat diseases at an earlier stage.
The company's flagship product is the Simoa system, which is a fully automated digital immunoassay platform that can detect and measure low-abundance biomolecules with unprecedented sensitivity.
Simoa uses single-molecule detection technology to accurately quantify proteins, DNA, and RNA molecules in biological samples, allowing scientists and clinicians to gain new insights into disease mechanisms and improve disease diagnosis and treatment.
Quanterix Corp's technology has a wide range of applications, including oncology, neurology, cardiology, infectious diseases, inflammation, and autoimmune diseases.
The company collaborates with leading academic institutions, pharmaceutical companies, and diagnostic companies to validate its technology and develop innovative diagnostic assays.
Quanterix Corp has received numerous awards for its technology, including being named a Technology Pioneer by the World Economic Forum, one of the 50 Smartest Companies by MIT Technology Review, and one of the Top 10 Innovations of the Year by The Scientist magazine.
The company is headquartered in Billerica, Massachusetts, and has offices and subsidiaries in Europe and Asia.
Quanterix Corp is well-established as a prominent player in the healthcare technology domain, committed to delivering ultra-sensitive diagnostic tests capable of identifying diseases at their nascent stages. The organizations mission centers on transforming precision medicine through the development and provision of life sciences tools and solutions that facilitate disease investigation, ultimately contributing to enhanced understanding, diagnosis, and treatment of patients. Quanterixs offerings span various segments, products, and services carefully curated to cater to the diverse needs of its clientele.
Segments
1. Life Sciences Research:
In the life sciences research segment, Quanterix delivers a variety of reagents, assays, and imaging consumables along with its flagship immunoassay platform known as Simoa (Single Molecule Array). This platform distinguishes itself by its ability to detect and quantify proteins and other molecules at exceedingly low concentrations, which is crucial for researchers aiming to delve deep into disease mechanisms and pathways. This segment supports a broad spectrum of research including drug discovery and development, biomarker validation, and clinical trial sample analysis.
2. In Vitro Diagnostics (IVD):
Quanterix is at the vanguard of the in vitro diagnostics segment, focusing on the development, manufacture, and distribution of ultra-sensitive diagnostic tests that can potentially detect diseases long before conventional methods. The IVD offerings incorporate a variety of Simoa-based tests catering to multiple medical fields, such as:
- Cardiology: Tests aimed at heart diseases, measuring biomarkers related to cardiac health.
- Neurology: Diagnostic assays that focus on neurodegenerative diseases such as Alzheimer’s and Multiple Sclerosis.
- Oncology: Tests that are designed for the detection of cancer-associated biomarkers, thereby aiding in early diagnosis and treatment decisions.
- Infectious Diseases: Simoa assays that assist in the detection and quantification of pathogens or markers associated with infectious diseases.
Products
1. Simoa HD-X Analyzer:
This state-of-the-art analyzer is pivotal in Quanterixs offering. The HD-X Analyzer is noted for its unparalleled sensitivity, allowing for the detection and quantification of proteins and other molecules at extremely low concentrations. Its high throughput and reproducibility make it a vital tool for both research and clinical laboratories in the quest to uncover disease insights.
2. Simoa Assays:
Quanterix offers a comprehensive suite of Simoa assays tailored to different applications. These assays utilize the HD-X Analyzers capabilities and span various medical domains such as cardiology, oncology, infectious diseases, and neurology. Each assay is designed to facilitate the detection of biomarkers that are critical for understanding disease progression and treatment efficacy.
3. Quanterix Homebrew Kits:
These kits empower researchers with the autonomy to develop custom assays tailored to their unique research needs. Utilizing the Simoa technology, the homebrew kits provide the flexibility necessary for research teams to innovate and explore specific biomarkers of interest.
Services
1. Assay Development Services:
Quanterix offers expert guidance and support in assay development through services that allow collaboration with their knowledgeable scientists. This personalized service aids researchers in developing and optimizing custom assays capable of detecting particular biomarkers pertinent to their studies.
2. Contract Research Services:
Through its contract research offerings, Quanterix supports clients in various research endeavors. The services encompass a broad spectrum, including assay development, sample analysis, and comprehensive data analysis, facilitating a full research cycle from development to actionable insights.
3. Technical Support Services:
Understanding that effective utilization of their products and services is crucial, Quanterix provides extensive technical support to address queries and concerns that customers may have. This ensures that clients can maximize the potential of their Quanterix solutions and streamline their research and diagnostic processes.
Conclusion
Overall, Quanterix Corp presents an extensive range of life science tools, innovative technologies, potent products, and supportive services. This comprehensive portfolio is strategically designed to empower researchers, clinicians, and diagnostic laboratories to deepen their understanding of various diseases, develop novel therapeutic approaches, and enhance disease diagnosis through the pioneering Simoa technology. Quanterix’s commitment to advancing healthcare through precision medicine continues to make a significant impact in both research and clinical settings.
Segments
1. Life Sciences Research:
In the life sciences research segment, Quanterix delivers a variety of reagents, assays, and imaging consumables along with its flagship immunoassay platform known as Simoa (Single Molecule Array). This platform distinguishes itself by its ability to detect and quantify proteins and other molecules at exceedingly low concentrations, which is crucial for researchers aiming to delve deep into disease mechanisms and pathways. This segment supports a broad spectrum of research including drug discovery and development, biomarker validation, and clinical trial sample analysis.
2. In Vitro Diagnostics (IVD):
Quanterix is at the vanguard of the in vitro diagnostics segment, focusing on the development, manufacture, and distribution of ultra-sensitive diagnostic tests that can potentially detect diseases long before conventional methods. The IVD offerings incorporate a variety of Simoa-based tests catering to multiple medical fields, such as:
- Cardiology: Tests aimed at heart diseases, measuring biomarkers related to cardiac health.
- Neurology: Diagnostic assays that focus on neurodegenerative diseases such as Alzheimer’s and Multiple Sclerosis.
- Oncology: Tests that are designed for the detection of cancer-associated biomarkers, thereby aiding in early diagnosis and treatment decisions.
- Infectious Diseases: Simoa assays that assist in the detection and quantification of pathogens or markers associated with infectious diseases.
Products
1. Simoa HD-X Analyzer:
This state-of-the-art analyzer is pivotal in Quanterixs offering. The HD-X Analyzer is noted for its unparalleled sensitivity, allowing for the detection and quantification of proteins and other molecules at extremely low concentrations. Its high throughput and reproducibility make it a vital tool for both research and clinical laboratories in the quest to uncover disease insights.
2. Simoa Assays:
Quanterix offers a comprehensive suite of Simoa assays tailored to different applications. These assays utilize the HD-X Analyzers capabilities and span various medical domains such as cardiology, oncology, infectious diseases, and neurology. Each assay is designed to facilitate the detection of biomarkers that are critical for understanding disease progression and treatment efficacy.
3. Quanterix Homebrew Kits:
These kits empower researchers with the autonomy to develop custom assays tailored to their unique research needs. Utilizing the Simoa technology, the homebrew kits provide the flexibility necessary for research teams to innovate and explore specific biomarkers of interest.
Services
1. Assay Development Services:
Quanterix offers expert guidance and support in assay development through services that allow collaboration with their knowledgeable scientists. This personalized service aids researchers in developing and optimizing custom assays capable of detecting particular biomarkers pertinent to their studies.
2. Contract Research Services:
Through its contract research offerings, Quanterix supports clients in various research endeavors. The services encompass a broad spectrum, including assay development, sample analysis, and comprehensive data analysis, facilitating a full research cycle from development to actionable insights.
3. Technical Support Services:
Understanding that effective utilization of their products and services is crucial, Quanterix provides extensive technical support to address queries and concerns that customers may have. This ensures that clients can maximize the potential of their Quanterix solutions and streamline their research and diagnostic processes.
Conclusion
Overall, Quanterix Corp presents an extensive range of life science tools, innovative technologies, potent products, and supportive services. This comprehensive portfolio is strategically designed to empower researchers, clinicians, and diagnostic laboratories to deepen their understanding of various diseases, develop novel therapeutic approaches, and enhance disease diagnosis through the pioneering Simoa technology. Quanterix’s commitment to advancing healthcare through precision medicine continues to make a significant impact in both research and clinical settings.